ArticleFrontiers in public health2026
Burden of hepatitis B virus-associated liver cancer in Asia: findings from the global burden of disease study.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends and disparities in hepatitis B burden in the Western Pacific Region, 2015-2024: a subregional analysis using modelled data.The Lancet regional health. Western Pacific · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus (HBV) infection is widespread in Asia. Of the many chronic diseases linked to HBV, among the most important is liver cancer. This study analysed the disease burden of chronic hepatitis B-associated liver cancer in Asia from 1990 to 2021. Methods: Data were obtained from the 2021 Global Burden of Disease study. We analyzed incidence, prevalence, deaths and disability-adjusted life years (DALYs) in Asian regions and countries from 1990 to 2021 by age and sex. Data processing and graph construction were performed using RStudio and BioWinford. The Joinpoint regression model was used to analyse the temporal data trends. Results: From 1990 to 2021, the disease burden of hepatitis B-related liver cancer in Asia decreased. A decline was observed in the rates of incidence (AAPC: -0.6), prevalence (AAPC: -0.1), deaths (AAPC: -1.0), and DALYs (AAPC: -1.2), even though their absolute numbers all increased. The number of incidence, prevalence, deaths and DALYs is highest among the middle-aged and older adults, and the highest rate is found among the older adults. Both the number and rate are highest in East Asia. Disease burdens differ by country. Discussion: The burden of hepatitis B-associated liver cancer in Asia has decreased over the past three decades, but remains non-negligible. Asian countries need to take corresponding measures against hepatitis B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.